The hypoglycemic effect of the PEGylated FGF-21

Progress in Biochemistry and Biophysics

Volumn 40, Issue 4, 2013, Pages 374-385

  Ye, Xian Long ^a   Zhao, Jing Zhuang ^a   Ren, Gui Ping ^a   Yu, Dan ^a   Liu, Ming Yao ^a   Yu, Yin Hang ^a   Li, De Shan ^a  

^a NORTHEAST AGRICULTURAL UNIVERSITY   (China)

Author keywords

FGF 21; Glucose uptake; Immunogenicity; PEGylation; Purification; Stability; Type 2 diabetes

Indexed keywords

EID: 84879740460     PISSN: 10003282     EISSN: None     Source Type: Journal    
DOI: 10.3724/SP.J.1206.2012.00397     Document Type: Article

References (17)

1. Walsh G. Biopharmaceutical benchmarks. Nature Biotechnology, 2000, 18:831-833
2. Subramanian M G, Fiscella M, Lamouse-Smith A, et al. Albinterfero-2b: a genetic fusion protein for the treatment of chronic hepatitis C. Nat Biotechnol, 2007, 25(12):1411-1419
3. Nucci M L, Shor T R, Abuchowski A. The therapeutic value of poly (ethylene glycol)-modified proteins. Adv Drug Deliv Rev, 1991, 6(2):133-151
4. Zhang M. PEGylation of insulin and the hypoglycemic effect of the PEGylated insulin[D], Shanghai: Fudan university, 2006
5. Francesco M, Veronese J, Milton Harris. Introduction and overview of peptide and protein pegylation. Advanced Drug Delivery Reviews, 2002, 54(4):453-456
6. Abuchowski A, Es T V, Palczuk N C, et al. Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J Biol Chem, 1977, 252:3578-3581
7. Roberts M J, Bentley M D, Harris J M. Chemistry for peptide and protein PEGylation. Advanced Drug Delivery Reviews, 2002, 54(4):459-476
8. Reddy K. R. Controlleed-release, pegylation, liposomal formulations: new mechanisms in the delivery of injectable drugs. Ann Pharmacother, 2000, 34(2):915-920
9. Nishimura T, Nakatake Y, Konishi M, et al. Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim Biophys Acta, 2000, 1492(1):203-206
10. Jiang Y Y, Liu M Y, Ren G P, et al. Prog Biochem Biophys, 2009, 36(2):157-164
11. Huang Z, Wang H, Lu M, et al. A Better anti-diabetic recombinant human fibroblast growth factor 21 (rhFGF21) modified with polyethylene glycol. PLoS ONE, 2011, 6(6):e20669
12. Liu M Y, Wang W F, Yu Y X, et al. Prog Biochem Biophys, 2009, 36(10):1327-1333
13. Wang X D, Li X H, Su Z G, et al. China Biotechnology, 2010, 30(4):101-109
14. Li W J, Lin B C, Su Z G. Chin J Anal Chem, 2001, 29(2):228-231
15. Malik F, Delgao C, Knusli C, et al. Polyethylene glycol (PEG) - modofïed granulocyte-macrophage colony-stimulating factor (GM-CSF) with conserved iological activity. Exp Hematol, 1992, 20(8):1028-1035
16. Liu L J, Zhao L C, Zhu X, et al. Chin J Biologicals, 2001, 14(4):210-212
17. Shi X F, Zhan J R, Liao B R. Shanghai Chemical Industry, 2007, 32(12):30-32 Commission